Cancer Clinical Trial - Plexxikon PLX120-03

Cancer

Status:

Open (Study open and enrolling)

ClinicalTrials.gov:

NCT02428712

The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX8394.

Drug

PLX8394

Trial Type

Interventional

Age Range

18 years or older

Phase

Phase 1/2a

Condition

Solid Tumors

Keywords

Plexxikon | BRAF | adenomcarcinoma | refractory